• Home

  • Documents

  • PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival...
26
PEMBRO vs NIVO: qual a melhor imunoterapia em pacientes com MSI-High? Evanius Wiermann Curitiba/PR II ECIP, 09 de março de 2018

PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3

Embed Size (px)

Citation preview

Page 1: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3

PEMBRO vs NIVO:

qual a melhor imunoterapia

em pacientes com MSI-High?

Evanius Wiermann

Curitiba/PR

II ECIP, 09 de março de 2018

Page 2: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3

MSI Status and Immunologic Response

Page 3: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 4: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 5: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 6: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 7: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 8: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 9: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 10: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 11: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 12: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 13: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 14: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3

Pembrolizumab Updates

Page 15: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 16: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 17: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 18: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3

Nivolumab Updates

Page 19: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 20: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 21: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 22: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 23: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 24: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 25: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3
Page 26: PEMBRO vs NIVO: qual a melhor imunoterapia em … · MSI-H patients seem to have improved survival when treated with bevacizumab compared to ... MLW MSH2 MSH6 MSH6 MLHt PMS2Jt usH3

Cancer-driving H3G34V/R/D mutations block H3K36 ... · mutations inhibit H3K36 trimethylation in vivo and in vitro. H3G34 Mutations Inhibit Interaction Between H3K36 and MSH6. To

Cancer-driving H3G34V/R/D mutations block H3K36 ... · mutations inhibit H3K36 trimethylation in vivo and in vitro. H3G34 Mutations Inhibit Interaction Between H3K36 and MSH6. To

Documents
Novel MSH6 MutationsinTreatment …clincancerres.aacrjournals.org/content/clincanres/20/18/4894.full.pdf · NovelMSH6MutationsinTreatment-NaïveGlioblastomaand Anaplastic Oligodendroglioma

Novel MSH6 MutationsinTreatment …clincancerres.aacrjournals.org/content/clincanres/20/18/4894.full.pdf · NovelMSH6MutationsinTreatment-NaïveGlioblastomaand Anaplastic Oligodendroglioma

Documents
Neoadjuverende behandling - DBCG Filer/Biomarkoerer_AVL.pdf · Immune check point inhibitor Neoadjuvant trial. KEYNOTE-522 study design • Median follow-up 15.8 mo, Pembro + chemo,

Neoadjuverende behandling - DBCG Filer/Biomarkoerer_AVL.pdf · Immune check point inhibitor Neoadjuvant trial. KEYNOTE-522 study design • Median follow-up 15.8 mo, Pembro + chemo,

Documents
Molecular testing in GI cancer - University of Utaharup.utah.edu/media/pc15_moleTestGI/Feb 12th 7 AM - Samowitz.pdf2013) •Decreased MSH6 staining after chemoradiation (Bao, Am J

Molecular testing in GI cancer - University of Utaharup.utah.edu/media/pc15_moleTestGI/Feb 12th 7 AM - Samowitz.pdf2013) •Decreased MSH6 staining after chemoradiation (Bao, Am J

Documents
Centers for Medicare and Medicaid Services · Association for Molecular Pathology, Presenter: Patel, Jay. Code # Public Comment . Rationale . 8X003. 81298 - MSH6 (mutShomolog 6 [E

Centers for Medicare and Medicaid Services · Association for Molecular Pathology, Presenter: Patel, Jay. Code # Public Comment . Rationale . 8X003. 81298 - MSH6 (mutShomolog 6 [E

Documents
RESEARCH Open Access CoDP: predicting the impact of ... · RESEARCH Open Access CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different

RESEARCH Open Access CoDP: predicting the impact of ... · RESEARCH Open Access CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different

Documents
ACCELERATED BUILD-UP SCHEDULES OF SPECIFIC … · imunoterapia específica envolvendo doentes com menos de 18 anos, para poder concluir afirmativamente que estes esquemas, além de

ACCELERATED BUILD-UP SCHEDULES OF SPECIFIC … · imunoterapia específica envolvendo doentes com menos de 18 anos, para poder concluir afirmativamente que estes esquemas, além de

Documents
Research Paper Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: … · Bcl-2 increased after MSH6 alteration (Table S1). All of these results indicated that MSH6 may be involved in regulating

Research Paper Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: … · Bcl-2 increased after MSH6 alteration (Table S1). All of these results indicated that MSH6 may be involved in regulating

Documents
Supporting Figure S1A Scatter plots of MSH6 expression against the café-au-lait macule burden (CALM) phenotype. The upper panel of plots represents the

Supporting Figure S1A Scatter plots of MSH6 expression against the café-au-lait macule burden (CALM) phenotype. The upper panel of plots represents the

Documents
Intended Use Table 1 - accessdata.fda.gov · atm ccnd1 ctnna1 fancg gnaq kel msh3 parp2 rac1 smo wt1 atr ccnd2 ctnnb1 fancl gnas kit msh6 parp3 rad21 sncaip xpo1 atrx ccnd3 cul3 fas

Intended Use Table 1 - accessdata.fda.gov · atm ccnd1 ctnna1 fancg gnaq kel msh3 parp2 rac1 smo wt1 atr ccnd2 ctnnb1 fancl gnas kit msh6 parp3 rad21 sncaip xpo1 atrx ccnd3 cul3 fas

Documents
Melanoma, o status da imunoterapia e o futuro próximosimposioimunooncologia.com.br/temas/imunooncologia/arquivos... · III International Symposium on Immuno-Oncology Saturday, October

Melanoma, o status da imunoterapia e o futuro próximosimposioimunooncologia.com.br/temas/imunooncologia/arquivos... · III International Symposium on Immuno-Oncology Saturday, October

Documents
Federally Designated Primary Care Health Professional Shortage … · 2011-11-10 · Pembro ke Tresco t Twp Lubec A lexand er Bail eyvil le T24 MD BPP T30 MD B P Cu tle r Falmout

Federally Designated Primary Care Health Professional Shortage … · 2011-11-10 · Pembro ke Tresco t Twp Lubec A lexand er Bail eyvil le T24 MD BPP T30 MD B P Cu tle r Falmout

Documents
MLH1, MSH2, MSH6, and PMS2 - Conference Innovators...Pros and cons of full-length transcript analysis •discrimination against PMS2 pseudogenes •needs informative variant for significant

MLH1, MSH2, MSH6, and PMS2 - Conference Innovators...Pros and cons of full-length transcript analysis •discrimination against PMS2 pseudogenes •needs informative variant for significant

Documents
sowie Version 2019.1D Brustkrebsrisiko und Prävention€¦ · kit max men1 met mlh1 msh2 msh6 mutyh nbn nf1 nf2 nsd1 palb2 phox2b pms1 pms2 prf1 prkar1a ptch1 pten rad51c rad51d

sowie Version 2019.1D Brustkrebsrisiko und Prävention€¦ · kit max men1 met mlh1 msh2 msh6 mutyh nbn nf1 nf2 nsd1 palb2 phox2b pms1 pms2 prf1 prkar1a ptch1 pten rad51c rad51d

Documents
Epithelial-stromal interaction in the pathogenesis of colorectal … · 2017. 12. 15. · MSH m utS homolog MSH2 mutS homolog 2 . 14 MSH6 mutS homolog 6 MSI microsatellite instability

Epithelial-stromal interaction in the pathogenesis of colorectal … · 2017. 12. 15. · MSH m utS homolog MSH2 mutS homolog 2 . 14 MSH6 mutS homolog 6 MSI microsatellite instability

Documents
Suspected Lynch syndrome associated MSH6 variants: A … · 2017-06-21 · RESEARCH ARTICLE Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their

Suspected Lynch syndrome associated MSH6 variants: A … · 2017-06-21 · RESEARCH ARTICLE Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their

Documents
IMUNOTERAPIA NO TRATAMENTO DO PACIENTE COM …congressomineirouro.com.br/wp-content/uploads/2016/08/09h35-Luiz... · Burnet e Thomas: ² o sistema ... In: Prendergast GC et al. Cancer

IMUNOTERAPIA NO TRATAMENTO DO PACIENTE COM …congressomineirouro.com.br/wp-content/uploads/2016/08/09h35-Luiz... · Burnet e Thomas: ² o sistema ... In: Prendergast GC et al. Cancer

Documents
IMMUNOTHERAPY IN METASTATIC COLORECTAL CANCER … · Unresectable or Metastatic Colorectal Cancer (KEYNOTE-164) NCT02460198 Phase 2 dMMR Refractory Pembro SOC Phase II Study to Evaluate

IMMUNOTHERAPY IN METASTATIC COLORECTAL CANCER … · Unresectable or Metastatic Colorectal Cancer (KEYNOTE-164) NCT02460198 Phase 2 dMMR Refractory Pembro SOC Phase II Study to Evaluate

Documents
GENÔMICA E MEDICINA DE PRECISÃO · 2015-12-01 · Síndrome de Li-Fraumeni TP53 Lynch Síndrome MLH1, MSH2, MSH6, ... Outros sintomas relatados pelo médico assistente: ... a partir

GENÔMICA E MEDICINA DE PRECISÃO · 2015-12-01 · Síndrome de Li-Fraumeni TP53 Lynch Síndrome MLH1, MSH2, MSH6, ... Outros sintomas relatados pelo médico assistente: ... a partir

Documents
THE CHALLENGES OF MEASURING THE RESPONSE TO ...MM33 Veh. + Pembro. Low IL2: TILs High IL2: TILs High IL2: TILs + Pembro. TILs n.s. p=0,007 0 10 20 30 40 50 60 70 0 100 200 300 Days

THE CHALLENGES OF MEASURING THE RESPONSE TO ...MM33 Veh. + Pembro. Low IL2: TILs High IL2: TILs High IL2: TILs + Pembro. TILs n.s. p=0,007 0 10 20 30 40 50 60 70 0 100 200 300 Days

Documents
SESSION 4 - OncologyPRO · SESSION 4 Systemic chemotherapy is NOT the standard of care in metastatic urothelial cancer ... Carbo/Gem 1 MCAVI 1 VFL/Gem 2* VFL/Carbo 2* Pembro 3 Atezolizumab

SESSION 4 - OncologyPRO · SESSION 4 Systemic chemotherapy is NOT the standard of care in metastatic urothelial cancer ... Carbo/Gem 1 MCAVI 1 VFL/Gem 2* VFL/Carbo 2* Pembro 3 Atezolizumab

Documents
Supplemental Digtal Content Teaching Case #6, Figure 6.1 MSH6

Supplemental Digtal Content Teaching Case #6, Figure 6.1 MSH6

Documents
Tolerability and activity of chemo-free triplet ... › Mato U2 Pembro Lugano 2019 Fina… · Prior Chemo Regimen 9 (100%) Prior idelalisib + rituximab 2 (22%) Prior venetoclax 3

Tolerability and activity of chemo-free triplet ... › Mato U2 Pembro Lugano 2019 Fina… · Prior Chemo Regimen 9 (100%) Prior idelalisib + rituximab 2 (22%) Prior venetoclax 3

Documents
Human Cancer Biology Clinical Cancer Research MSH6 and ... · Human Cancer Biology MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer María Dolores Giráldez

Human Cancer Biology Clinical Cancer Research MSH6 and ... · Human Cancer Biology MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer María Dolores Giráldez

Documents
Pembrolizumab for Classical Hodgkin lymphomaaimwithimmunotherapy.org/wp-content/uploads/2018/10/Pembro-cHL-Toolkit-Final.pdf · blocking the inhibitory pathway and releasing the immune

Pembrolizumab for Classical Hodgkin lymphomaaimwithimmunotherapy.org/wp-content/uploads/2018/10/Pembro-cHL-Toolkit-Final.pdf · blocking the inhibitory pathway and releasing the immune

Documents
Roles of MSH2 and MSH6 in cadmium-induced G2/M checkpoint ...orca.cf.ac.uk/113831/1/Roles of MSH2 and MSH6 in... · 15 T D ACCEPTED MANUSCRIPT 1 1 Roles of MSH2 and MSH6 in Cadmium-induced

Roles of MSH2 and MSH6 in cadmium-induced G2/M checkpoint ...orca.cf.ac.uk/113831/1/Roles of MSH2 and MSH6 in... · 15 T D ACCEPTED MANUSCRIPT 1 1 Roles of MSH2 and MSH6 in Cadmium-induced

Documents
The global leader in LAG-3 therapeutics · Randomized, placebo controlled. OS data due December 2020. TACTI-002 –Efti + Pembro Phase II in 1st and 2nd line NSCLC 1st line NSCLC:

The global leader in LAG-3 therapeutics · Randomized, placebo controlled. OS data due December 2020. TACTI-002 –Efti + Pembro Phase II in 1st and 2nd line NSCLC 1st line NSCLC:

Documents
Efficacy/safety of entinostat (ENT) and pembrolizumab ...€¦ · Efficacy/safety of entinostat (ENT) and pembrolizumab (PEMBRO) in NSCLC patients previously treated with anti -PD-(L)1

Efficacy/safety of entinostat (ENT) and pembrolizumab ...€¦ · Efficacy/safety of entinostat (ENT) and pembrolizumab (PEMBRO) in NSCLC patients previously treated with anti -PD-(L)1

Documents
Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic

Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic

Documents
PTPN12 MSH6 ,and - Hindawi Publishing Corporationdownloads.hindawi.com/journals/bmri/2013/902467.pdf · BioMed Research International T : Characteristics of miR- binding sites in

PTPN12 MSH6 ,and - Hindawi Publishing Corporationdownloads.hindawi.com/journals/bmri/2013/902467.pdf · BioMed Research International T : Characteristics of miR- binding sites in

Documents